Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis

Abstract

ABSTRACT.Purpose: To compare the therapeutic effects of two ophthalmic solutions (0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine) with different pharmacological mechanisms on the clinical signs and Symptoms of seasonal allergic conjunctivitis (SAC). Methods: Forty patients with the signs and symptoms of SAC (i.e. hyperaemia, itching, mucus discharge, tearing) were included in this placebo-controlled, randomized, parallel group, single centre study. In group 1 (20 patients) one eye of each patient was treated with olopatadine and the other with placebo. In group 2 (20 patients) one eye of each patient was treated with ketorolac solution and the other with placebo. The principal signs and symptoms of SAC (hyperaemia and itching) were evaluated at 30 mins and at 2, 7 and 15 days. Results: In group 1, both parameters improved significantly in eyes treated with olopatadine compared with those receiving placebo at all control examinations (all p < 0.05). Similarly, eyes treated with ketorolac showed significant reductions in signs and symptoms compared with those receiving placebo (all p < 0.05). When the clinical parameters of eyes treated with olopatadine were compared with those treated with ketorolac, the mean score of hyperaemia was found to be lower in the olopatadine group, but the difference was not statistically significant (all p > 0.05). However, the itching score was significantly lower in the olopatadine group from the second day through to the end of the study (p < 0.05). Conclusions: Both olopatadine and ketorolac ophthalmic solutions were found to be effective in alleviating the clinical signs and symptoms of SAC compared to placebo. However, olopatadine reduces ocular itching significantly more than ketorolac.

Plasma vitamin D and serum total immunoglobulin E levels in patients with seasonal allergic conjunctivitis

“…All patients were recruited in the study in May 2013, during the peak spring allergy season in Turkey (Yaylali et al 2003), and evaluated at the Mevlana University eye clinic. Patients with a history of SAC of ≥2 years' duration, with moderate or severe signs and symptoms of clinically active allergic conjunctivitis (conjunctival hyperaemia, itching, tearing, chemosis or lid oedema) and a positive skin prick test to at least one antigen common in the geographical area were included in the SAC group.…”

Efficacy and safety comparison of topical loteprednol and topical non-steroidal anti-inflammatory drugs in seasonal allergic conjunctivitis: a prospective open label comparative study

“…In allergic conjunctivitis diclofenac and ketorolac were similar in relieving the symptoms particularly itching, and some studies have shown superiority of ketorolac in relieving ocular itching. 14,4,9,15 The efficacy of topical NSAIDs particularly ketorolac in relieving ocular itching is probably related to the decreased synthesis of pruritogenic PGs-PGE-2 and PGI-2. 4 In several other studies ketorolac was found to be most effective among the topical NSAIDs in relieving ocular symptoms, particularly itching.…”

A prospective study of efficacy and safety of olopatadine versus azelastine in allergic conjunctivitis at a tertiary care hospital

“…Demographic data, ocular and medical history, concomitant medications, physical examination, clinical examination including recording of vital signs, ophthalmological examination (ocular sign and symptom score) and details of drug prescription were recorded in the study proforma at baseline visit (visit 1) and all subsequent follow-up visits. [10][11][12][13] Follow-up visits were done on day 8 (visit 2) and day 15 (visit 3) after administering the study drugs. A deviation of ±1 day for first follow-up and ±2 days for subsequent follow-up was accepted.…”